Vardenafil and avanafil are prescription oral PDE5 inhibitors for erectile dysfunction, usually discussed as as-needed options rather than daily maintenance medicines. Their brand histories are different: Levitra and Staxyn are discontinued U.S. vardenafil brands, although FDA-approved generic vardenafil products exist; Stendra is the avanafil brand, with separately approved generic avanafil tablets. A familiar brand name does not confirm current pharmacy inventory.
The comparison is particularly important for patients with cardiac rhythm concerns. Vardenafil labeling contains a specific warning concerning QT prolongation and recommends avoidance in people with congenital long QT syndrome or taking certain class IA or class III antiarrhythmics. Avanafil also has serious interaction restrictions, but a patient should not assume that the absence of identical QT language establishes it as safe for any particular heart condition.
This page compares two active ingredients and their approved ED-use contexts. Vardenafil ODT is a formulation-specific topic, while avanafil pharmacy access addresses prescription dispensing. Neither drug is an OTC treatment, and no timing statistic guarantees efficacy.
The table distinguishes the ordinary vardenafil tablet from vardenafil ODT because the two 10 mg forms are not automatically substitutable. Avanafil is a different active ingredient altogether. The comparison is informational; it cannot determine a safe individual dose or predict a faster response.
Historical brand names are included only to explain why older articles still mention them. Availability must be checked against current FDA records and actual pharmacy inventory.
| Clinical or pharmacy factor | Vardenafil | Avanafil |
|---|---|---|
| Indication | ED in adults; as needed | ED in adults; as needed |
| Film-coated/oral strength family | 2.5, 5, 10 and 20 mg film-coated legacy/current approved listings vary | 50, 100 and 200 mg oral tablets |
| Common label timing | Approximately 60 minutes before sexual activity for film-coated tablets | As early as about 15 minutes with specified strengths; 50 mg about 30 minutes |
| QT consideration | Specific congenital QT and class IA/III antiarrhythmic caution | Individual cardiovascular and interaction screening still necessary |
| U.S. brands | Original Levitra and Staxyn brands discontinued | Stendra; approved generic avanafil exists |
| Special formulation issue | 10 mg ODT and 10 mg film-coated tablets not interchangeable | Distinct oral tablets; not a vardenafil substitute |
Vardenafil film-coated tablet labeling generally describes administration about an hour before sexual activity. Avanafil's earliest stated administration interval is approximately 15 minutes for certain strengths, with different wording for its lower-strength presentation. These are manufacturer-labeled recommendations, not a randomized head-to-head demonstration that one drug causes erections a fixed number of minutes earlier.
Clinical onset depends on arousal, comorbidity, food, accompanying medicines and individual response. Choosing an ED drug solely because its label uses a smaller lead-time number ignores safety, tolerability and the patient's previous treatment experience. The four-agent onset guide provides a wider frame.
Vardenafil prescribing information describes QTc findings and instructs that patients with congenital long QT syndrome or those taking class IA or class III antiarrhythmic medicines should avoid it. These cautions can affect a medication decision even when a patient has no obvious symptoms. Names such as amiodarone, sotalol, quinidine and procainamide are relevant to a clinician's review.
Do not infer that avanafil is a safe workaround for arrhythmia, structural heart disease or unstable cardiovascular conditions. Its own label still requires evaluation of whether sexual activity is advisable, whether nitrates or guanylate cyclase stimulators are used, and whether blood-pressure medicines or CYP3A4 inhibitors create serious interactions.
Both drugs are metabolized through CYP3A4, but their U.S. labeling does not assign the same management approach. Stendra/avanafil labeling says not to use it with strong CYP3A4 inhibitors such as ritonavir, ketoconazole or clarithromycin. For moderate CYP3A4 inhibitors, it provides a separate dose limit. The vardenafil film-coated label instead supplies highly restricted, drug-specific dose and interval rules for some such combinations, including ritonavir or cobicistat. Those labeled rules cannot be transferred between the drugs.
A patient who starts an antiviral, azole antifungal or other CYP3A4-affecting medicine should ask the prescriber and pharmacist to recheck the exact product and full regimen. The difference is a safety distinction, not an endorsement of trying the combination or calculating a new dose at home. Vardenafil interactions covers its formulation-specific rules.
| Interaction consideration | Vardenafil film-coated tablets | Avanafil tablets |
|---|---|---|
| Strong CYP3A4 inhibitor | Specific drug-dependent maximums and intervals in label; clinical review essential | Do not use with strong CYP3A4 inhibitors per label |
| Moderate CYP3A4 inhibitor | Drug-dependent dose and interval restrictions | Specific dose restriction in label |
| Patient action | Ask about exact formulation and medication | Ask about exact medication and avoid self-adjustment |
Vardenafil 10 mg orally disintegrating tablets are a different product form from conventional film-coated vardenafil 10 mg tablets; the labels do not permit automatic milligram-for-milligram substitution. They also have distinct administration instructions and pharmacokinetic properties. Old Staxyn branding should not be treated as proof that a particular ODT product is still marketed.
A person holding a prescription for the film-coated form should ask the pharmacist about the exact authorized product rather than demand an ODT as an equivalent. Conversely, an ODT prescription does not permit a counter substitution to avanafil or conventional vardenafil without proper prescriber and pharmacy review.
Vardenafil film-coated labeling allows use with or without food, but high-fat meals can alter its absorption characteristics. Avanafil may also be taken with or without food, while a high-fat meal can affect some pharmacokinetic measurements. An absorption measurement should not be converted into a guarantee that the medicine will fail or work after an identical delay.
For patients seeking to understand their own experience, the timing of meals is a reasonable detail to report at a follow-up visit. It is not a reason to take additional tablets. See the vardenafil meal-specific page for formulation nuances.
Both drugs share the class-wide dangerous interaction with organic nitrates and soluble guanylate cyclase stimulators. Avanafil labeling specifically prohibits concurrent strong CYP3A4 inhibitors, while vardenafil requires its own inhibitor-related restrictions and dose considerations. Alpha-blocker therapy, antihypertensives and substantial alcohol use can further alter blood pressure risk.
A complete medication list should include intermittent nitroglycerin, recreational nitrite products, antiarrhythmics, antibiotics, antifungals and antiviral therapies. If chest pain develops after taking either ED medicine, seek emergency care and identify the exact PDE5 drug used; do not self-administer nitrates.
Headache, flushing, congestion, dizziness and gastrointestinal symptoms can occur with oral PDE5 inhibitors. Numbers reported in separate avanafil and vardenafil trials involve different participants, doses and study conditions, and therefore cannot establish which product is categorically safer. The presence of a QT warning is a specific prescribing factor, not a generic count of ordinary side effects.
Both require awareness of urgent visual or auditory changes and erections lasting more than four hours. Unexpected symptoms should prompt appropriate medical guidance; patients should not switch agents independently to test whether adverse effects improve.
Levitra is the historical brand of conventional vardenafil tablets, and Staxyn was the historical 10 mg orally disintegrating brand. The original U.S. brand presentations have been discontinued. Approved generic vardenafil records are distinct regulatory products; the FDA Orange Book can clarify approval and therapeutic-equivalence status but cannot show whether a nearby pharmacy has the precise form or strength on hand.
Stendra is the U.S. avanafil brand, and an FDA-approved generic avanafil application exists. Do not assume the brand or the generic is always supplied. The pharmacy should check the prescription, manufacturer, strength, package and availability and then provide its actual all-in quote.
A useful appointment focuses on the patient's heart and rhythm history, medications that might change QT or blood pressure, preferences for activity timing, past PDE5 experiences and the feasibility of the prescribed formulation. Someone with a known QT issue needs a clinician to assess that problem before comparing convenience claims.
The vardenafil prescribing guide describes clinical assessment generally, while this page supplies the avanafil comparison. Do not combine medicines, request an unsupervised switch between products or treat an online seller's equivalence claim as authoritative.
An exact comparison requires the prescribed ingredient, dosage form, strength, quantity, insurer rules, pharmacy fees, and confirmation of current fulfillment. Vardenafil ODT and film-coated prescriptions may face different dispensing circumstances. Stendra and generic avanafil may have different inventory and benefit rules, without one universally cheaper path.
Ask licensed pharmacies for current complete quotes for the prescribed alternatives and check substitution authorization before ordering. The cross-drug cost guide explains this verification method without publishing prices that will become stale.
No. Both are PDE5 inhibitors for ED, but they contain different active ingredients and have distinct FDA labels and interactions.
No. Certain strengths have earlier labeled administration instructions, but that does not guarantee a response at a precise time.
Vardenafil has a specific QT-related precaution. People with congenital long QT syndrome or particular antiarrhythmic medicines should avoid it under the label.
Not automatically. The two dosage forms are not interchangeable, even though their labeled milligram amounts match.
The original U.S. Levitra brand presentations are discontinued. Approved generic vardenafil products have a separate regulatory and supply status.
Yes. FDA approved a first generic avanafil application. That approval does not guarantee local dispensing inventory.
Neither can be selected safely from a general comparison. Cardiovascular status, sexual-activity risk, rhythm conditions and interacting medicines require clinician assessment.
Do not switch or combine PDE5 drugs without explicit medical guidance. They have different prescriptions and potential for overlapping adverse effects.